Insider Selling: Abeona Therapeutics Inc (NASDAQ:ABEO) Director Sells $20,400.00 in Stock

Abeona Therapeutics Inc (NASDAQ:ABEO) Director Mark Alvino sold 4,000 shares of the firm’s stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $5.10, for a total transaction of $20,400.00. Following the completion of the transaction, the director now owns 68,334 shares in the company, valued at $348,503.40. This represents a 5.53 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Abeona Therapeutics Stock Up 2.1 %

Shares of NASDAQ ABEO opened at $5.25 on Friday. The firm has a fifty day simple moving average of $5.78 and a two-hundred day simple moving average of $5.71. The firm has a market capitalization of $228.22 million, a PE ratio of -1.95 and a beta of 1.46. The company has a current ratio of 6.12, a quick ratio of 6.12 and a debt-to-equity ratio of 0.31. Abeona Therapeutics Inc has a 12 month low of $3.05 and a 12 month high of $9.01.

Hedge Funds Weigh In On Abeona Therapeutics

Institutional investors have recently bought and sold shares of the stock. Bank of New York Mellon Corp grew its holdings in shares of Abeona Therapeutics by 2.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 121,453 shares of the biopharmaceutical company’s stock worth $515,000 after acquiring an additional 2,434 shares during the period. Renaissance Technologies LLC boosted its position in shares of Abeona Therapeutics by 581.6% during the second quarter. Renaissance Technologies LLC now owns 503,293 shares of the biopharmaceutical company’s stock valued at $2,134,000 after purchasing an additional 429,456 shares in the last quarter. abrdn plc grew its stake in Abeona Therapeutics by 158.8% in the third quarter. abrdn plc now owns 326,995 shares of the biopharmaceutical company’s stock worth $2,067,000 after purchasing an additional 200,647 shares during the period. Rosalind Advisors Inc. raised its holdings in Abeona Therapeutics by 4.7% in the third quarter. Rosalind Advisors Inc. now owns 1,832,000 shares of the biopharmaceutical company’s stock worth $11,578,000 after purchasing an additional 82,000 shares in the last quarter. Finally, GSA Capital Partners LLP lifted its position in Abeona Therapeutics by 54.3% during the third quarter. GSA Capital Partners LLP now owns 96,092 shares of the biopharmaceutical company’s stock valued at $607,000 after buying an additional 33,831 shares during the period. 80.56% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the stock. Cantor Fitzgerald reissued an “overweight” rating and issued a $18.00 price target on shares of Abeona Therapeutics in a report on Tuesday, October 29th. HC Wainwright reissued a “buy” rating and issued a $15.00 target price on shares of Abeona Therapeutics in a research note on Monday, November 25th. Finally, StockNews.com lowered Abeona Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, January 9th.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.